Clinical Trial Update: Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NNC0194-0499, cagrilintide, and semaglutide, alone or in combinations, for liver damage and alcohol use in alcohol-related liver diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol-related Liver Disease

Drugs mentioned

• Cagrilintide (cagrilintide)
• NNC0194-0499
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Alcohol-related Liver Disease | Phase 2 | Status: COMPLETED